Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer

• DOI: 10.2147/ott.s349096
• Publication Date: 2022-03-16T07:30:08Z
• Authors: Li Dai; Xiangren Jin; Liuxing Wang; Haibin Wang; Zhiqiang Yan; Guanghai Wang; Baichuang Liang; Fu Huang; Yuling Luo; Taichun Chen; Qian Wang
• Keywords: Apatinib; Tegafur

Abstract: Currently, effective therapies for advanced gastric cancer with systemic metastasis are lacking. Pharmacological research has been slowly progressing over the past decades. Here, we report case of a 56-year-old female human epidermal growth factor receptor 2 (HER2) expression (IHC 2+/FISH-) in metastasis. The first-line therapeutic regime consisted administration camrelizumab, local arterial infusion oxaliplatin and embolization, oral apatinib, PS scheme (oral tegafur-gimeracil-oteracil (S-1) paclitaxel (PTX), which was administered both intraperitoneally systemically). After treatment, 3-month progression-free survival (PFS) observed. Due to occurrence CTCAE grade 4 adverse reactions, patient could not tolerate chemotherapy. In second line replaced disitamab vedotin continued use carrilizumab apatinib. four cycles, efficacy evaluation showed that it stable disease (SD), only 1/2 reactions occurred, endoscopy examination tumor control reduction ulcer lesion. At time submission current manuscript, 6-month PFS achieved treatment continued. safety observed our case, propose be promising drug patients HER2 expression. Keywords: cancer, 2,